24/7 Market News Snapshot 11 August, 2025 – Compass Therapeutics, Inc. Common Stock (NASDAQ:CMPX)

August 11, 2025

DENVER, Colo., 11 August, 2025 (www.247marketnews.com) – (NASDAQ:CMPX) are discussed in this article.
Compass Therapeutics, Inc. (CMPX) has demonstrated remarkable movement in the financial markets, opening today at $2.72 and currently trading at $3.225, marking a notable increase of 19.44%. This surge indicates robust buyer interest and momentum within the stock, especially following a previous close of $2.70. The trading volume for CMPX has reached 1.04 million shares, reflecting heightened investor activity that can contribute to price stability and liquidity. Key resistance levels are being observed above $3.30, while support is noted around the opening price of $2.72, presenting critical points for investors to consider in their trading strategies.

In conjunction with its market performance, Compass is advancing its clinical programs within the oncology sector. Recent updates from the company’s second quarter 2025 results highlight ongoing developments in its pipeline. Notably, in the Phase 2/3 trial of tovecimig, a DLL4 x VEGF-A bispecific antibody geared towards patients with advanced biliary tract cancer, early data suggests a lower-than-anticipated mortality rate, indicating potential improvements in overall survival for participants. Results from essential secondary endpoints are expected to be available by Q1 2026.

Additionally, in the Phase 1 dose-escalation study of CTX-8371, a PD-1 x PD-L1 bispecific antibody, preliminary findings showcase promising efficacy, with significant tumor reduction observed in two patients with distinct cancer types. The expansion of cohorts for these particular patients is scheduled to begin in Q4 2025.

Moreover, Compass is on track to submit an Investigational New Drug (IND) application for its innovative PD-1 x VEGF-A bispecific antibody, CTX-10726, by the end of 2025. Current data highlights its competitive edge over existing therapies in preclinical models.

Financially, Compass maintains a robust cash position of $101 million as of June 30, 2025, ensuring adequate funding for its development endeavors through 2027. Complete with a solid financial foundation and promising therapeutic pipeline, Compass Therapeutics is poised for significant advancements in cancer treatment and patient care.

Related news for (CMPX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.